GEA
IDXX icon

Glen Eagle Advisors’s Idexx Laboratories IDXX Stock Holding History

Glen Eagle Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
2,056
+2,026
+6,753% +$1.3M 0.16% 102
2025
Q4 		$20.3K Buy
+30
New +$20.4K ﹤0.01% 579
2024
Q4 		– Sell
-11
Closed -$5.56K – 1133
2024
Q3 		$5.56K Hold
11
– – ﹤0.01% 744
2024
Q2 		$5.36K Buy
+11
New +$5.52K ﹤0.01% 754
2019
Q3 		– Sell
-5
Closed -$1.38K – 837
2019
Q2 		$1.38K Sell
5
-1
-17% -$246 ﹤0.01% 719
2019
Q1 		$1.34K Hold
6
– – ﹤0.01% 682
2018
Q4 		$1.12K Hold
6
– – ﹤0.01% 668
2018
Q3 		$1.5K Hold
6
– – ﹤0.01% 648
2018
Q2 		$1.31K Buy
+6
New +$1.24K ﹤0.01% 639

Other funds holding IDXX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glen Eagle Advisors's IDXX Position: Q1 2026 in Review

Glen Eagle Advisors increased its Idexx Laboratories (IDXX) stake by 6,753% in Q1 2026, buying an estimated $1.3M and bringing the position to 2,056 shares worth $1.16M. The position accounts for 0.16% of the portfolio, ranked #102.

Glen Eagle Advisors first reported a position in IDXX in Q2 2018 and has held it in 9 quarters since. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Glen Eagle Advisors held 2,056 shares of Idexx Laboratories worth $1.16M as of Q1 2026.
  • Glen Eagle Advisors bought 2,026 Idexx Laboratories shares in Q1 2026, an estimated $1.3M.
  • Idexx Laboratories made up 0.16% of Glen Eagle Advisors's portfolio in Q1 2026, its #102 holding.
  • Glen Eagle Advisors first reported a position in Idexx Laboratories in Q2 2018 and has held it in 9 quarters since.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.